Calumet (CLMT) just closed FY 2025 with Q4 revenue of US$1,038.6 million and a basic EPS loss of US$0.43, while the trailing twelve months show revenue of US$4.1 billion and a basic EPS loss of US$0.39. Over recent quarters, quarterly revenue has ranged from US$993.9 million to US$1,078 million, with EPS swinging between a loss of US$1.87 and a gain of US$3.61. This sets the context for investors weighing the latest print against the current share price of US$34.61. In this backdrop, margins remain pressured, so the key question is how much of the long term earnings recovery story these results actually support.

See our full analysis for Calumet.

With the headline numbers on the table, the next step is to see how this earnings profile lines up with the prevailing Calumet narratives and where the latest figures confirm or challenge those stories.

TTM loss narrows to US$33.8 million

• On a trailing twelve month basis to Q4 FY 2025, Calumet reported revenue of US$4.1b and a net loss of US$33.8 million, compared with a quarterly Q4 FY 2025 loss of US$37.3 million on US$1,038.6 million of revenue.
• Consensus narrative points to future margin improvement, with analysts modeling revenue growth of 8% a year and margins moving from roughly -11.1% to 0.8%, while recent quarters still show losses in three out of four periods, which keeps the path from current loss making to that margin target an open question.
  • Across FY 2025, three quarters posted net losses between US$37.3 million and US$162 million, with only Q3 showing a profit of US$313.4 million, so earnings are still quite uneven against the smoother improvement analysts expect.
  • Over the last five years, losses are described as shrinking at about 10.5% a year, which supports the idea of gradual repair, but the current TTM loss and negative margins mean that improvement is not yet translating into consistent profitability.

Large EPS swings test the bullish view

• Basic EPS over FY 2025 moved from a loss of US$1.87 in Q1 to a gain of US$3.61 in Q3, then back to a loss of US$0.43 in Q4, while TTM EPS sits at a loss of US$0.39.
• Bulls focus on very strong earnings growth forecasts of about 134.49% a year and an expectation that Calumet becomes profitable within three years, yet the pattern of quarterly EPS flipping between losses and one strong positive quarter means recent results give only partial support to that smoother turnaround story.
  • The TTM loss of US$33.8 million is far smaller than the TTM loss of US$451.2 million seen earlier in FY 2025, which lines up with the bullish idea of improving earnings, but the return to a Q4 loss after a strong Q3 shows that progress is not linear.
  • With the stock at US$34.61 against an analyst price target of US$37.00, a lot of the forecasted recovery may already be reflected in the price, while the current loss making status and negative margins remain clear in the latest TTM figures.

On days like this, bulls argue that the recent narrowing of TTM losses could be an early sign of the earnings recovery they are counting on, so it is worth seeing how their full thesis connects the Montana Renewables ramp up, margin targets, and balance sheet repair to these reported numbers. 🐂 Calumet Bull Case

Negative equity keeps the bearish case in play

• Calumet reports negative shareholders’ equity alongside TTM revenue of US$4.1b and a TTM net loss of US$33.8 million, while the stock trades at a P/S of 0.7x, cheaper than the wider US Oil & Gas industry at 2.1x but at a premium to its 0.2x peer average.
• Bears highlight the combination of negative equity and current unprofitability as key financial risks, and the latest data still fits that concern, even though losses have been shrinking over five years and revenue is described as growing at about 5% a year, which together show some repair under way.
  • The 0.7x P/S ratio can look attractive next to the broader industry, yet the premium to the 0.2x peer average suggests some investors are already paying up relative to closer comparables despite the balance sheet weakness.
  • Earnings are forecast to swing into positive territory within three years, but until that shows up in actual TTM profits and equity turns positive, the current capital structure remains a central part of the risk story for anyone looking at the US$34.61 share price.

If you are weighing how much risk that negative equity represents compared with the potential for future earnings, it can help to see how skeptics frame the balance between leverage, regulation exposure, and current valuation. 🐻 Calumet Bear Case

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Calumet on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

Mixed signals or a clear direction: either way, this is your cue to move fast, review the numbers yourself, and see how they stack up against the balance of risks and rewards in the latest data with 2 key rewards and 1 important warning sign

See What Else Is Out There

Calumet still reports a TTM net loss, negative equity, volatile EPS and pressured margins, so its recovery story carries meaningful financial risk.

If that mix of losses and balance sheet strain makes you cautious, it is worth comparing Calumet against companies in the 72 resilient stocks with low risk scores to see options with more resilient profiles.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.